Activates both GLP-1 and glucagon receptors.
Chinese adults with overweight or obesity without diabetes
Study context4/6 mg approved for weight management in China; 9 mg supplemental application under review in latest located announcement.
Status sourceStatus & indications14.01% reported weight loss · 0.3% gain with placebo · 48 weeks
GLORY-1 · Phase 3 · peer-reviewed · 6 mg once weekly · Regardless of stopping treatment
Evidence & limitationsMost reported adverse events were mild or moderate gastrointestinal events.
Safety contextA next milestone is not summarized for this therapy.
Milestone detailsStudy results apply to their own population, dose and analysis. They do not establish a ranking between therapies.
Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.
14.01% reported weight loss · 0.3% gain with placebo · 48 weeks
6 mg once weekly
Chinese adults with overweight or obesity without diabetes
Includes early discontinuation and new obesity therapies. 4/6 mg approved for weight management in China; 9 mg supplemental application under review in latest located announcement.
Most reported adverse events were mild or moderate gastrointestinal events.
Limitations: China-only trial; placebo gained 0.30%.
19.6% reported weight loss · 2.79% loss with placebo · 60 weeks
9 mg once weekly
Prespecified subgroup without T2D; Chinese adults with BMI >=30; 257 active and 130 placebo
Includes early discontinuation and new obesity therapies. 4/6 mg approved for weight management in China; 9 mg supplemental application under review in latest located announcement.
Overall trial: vomiting 53.1%, nausea 46.9%, diarrhea 39.4%; 2.9% stopped drug for adverse events.
Limitations: Subgroup from mixed diabetes trial, not full trial population. Published treatment-policy estimate replaces sponsor 20.08% headline.
1.66 percentage-point HbA1c decrease · 1.36 pp decrease with Dulaglutide 1.5 mg weekly · 28 weeks
6 mg weekly
Chinese adults with type 2 diabetes inadequately controlled with oral antidiabetic therapy
Modified ITT treatment-policy analysis; includes data after discontinuation and rescue therapy.
Diarrhea, nausea and vomiting were common; GI events were more frequent than with dulaglutide.
Limitations: Dulaglutide arm open-label; mazdutide dose groups blinded. Trial-wide baseline. Registry title mentions TZD, whereas the published analysis plan specifies SGLT2 inhibitor or sulfonylurea.
Status in this atlas: 4/6 mg approved for weight management in China; 9 mg supplemental application under review in latest located announcement. Status source
Activates both GLP-1 and glucagon receptors.
Innovent Biologics · China development and commercialization licensee; licensed mazdutide from Lilly in 2019.; Eli Lilly and Company · Originator and licensor to Innovent for China development and commercialization.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
Activates both GLP-1 and glucagon receptors.
Shown: Peptide drug
A named PubChem record was found, but the complete peptide modifications and stereochemistry were not independently reconciled during this review; no exact-drug image is presented.
MazdutideMazdutide · compound history across indications
Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.
The approved Chinese prescribing information dates initial approval to June 24, 2025; Innovent publicly announced it on June 27.
SourceInnovent announced NMPA approval for glycemic control in adults with type 2 diabetes.
SourceJAMA published the 9 mg phase 3 trial, including a separately reported subgroup without diabetes.
SourceSelected sources checked Sep 13, 2026. This is not an exhaustive history.